Archive | Uncategorized

GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML

logo-glyco

Evaluating previously untreated newly diagnosed adults with acute myeloid leukemia (AML) who are fit for intensive chemotherapySecond initiation among three late-stage uproleselan clinical trials ROCKVILLE, Md.–(BUSINESS WIRE)–Apr. 23, 2019– GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a Cooperative Research and Development Agreement […]

Comments Off on GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML Continue Reading →

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

MAXCYTE-New-Logo-2016-LARGE

MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new ExPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, […]

Comments Off on MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies Continue Reading →

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing

Paragon

Appointments and Promotions Continue to Position Paragon as Industry-Leading Gene Therapy and Vaccine CDMO Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several key promotions and new hires. “We are thrilled to welcome Tom […]

Comments Off on Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing Continue Reading →

Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic

bluestar_jpg

Welldoc®, a leading digital health company, announced today that it has secured a technology patent (based on U.S. Patent Application No. 15/923,010) from the United States Patent and Trademark Office for the Software Engine Technology that powers its BlueStar® digital therapeutic. “The awarding of this tenth technology patent to Welldoc is a validation of our […]

Comments Off on Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic Continue Reading →

Viela Bio Spins Out of MedImmune

vielabio-logo-blue

Viela Bio Spins Out of MedImmune; Launches with Up to $250 Million Series A Financing from Investor Consortium Led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital Viela Bio team will focus on developing medicines for severe autoimmune diseases by targeting critical pathways that are the root cause of disease Gaithersburg, MD, February 28, 2018 – Viela Bio […]

Technical.ly Baltimore: Where Steve Case sees opportunity for Baltimore’s startup community

AnchorVentures-LinkedIn-ProfilePhoto

At this point, Steve Case has seen many startup communities, as his Rise of the Rest bus tour has been to 33 cities. Speaking Thursday at Johns Hopkins’ FastForward 1812 in East Baltimore on Thursday night, the AOL cofounder said each community has a unique story and opportunity for growth. As far as the prospects for Baltimore, he pointed to increasing work […]

Comments Off on Technical.ly Baltimore: Where Steve Case sees opportunity for Baltimore’s startup community Continue Reading →

UMB’s New Ventures Initiative Fosters Commercialization

umventures-logo-trans

Innovative science at the University of Maryland, Baltimore is getting an extra boost through an innovative program fueled by UM Ventures called the “New Ventures Initiative” (NVI), which is headquartered in the Lion Brothers Building.   UMB’s New Ventures Initiative is designed to bring together management expertise, business formation strategy, a physical space, and early-stage capital […]

Comments Off on UMB’s New Ventures Initiative Fosters Commercialization Continue Reading →

My Guest Post on BioBuzz: An Interview with Analytical Informatics, Inc. CEO Chris Meenan – Part One

In part one of this two-part series, I talked with Maryland health IT executive Chris Meenan about his company Analytical Informatics, Inc. (AI), and what it takes to be a successful entrepreneur. This is part of a broader interview series. Chief executive: Chris Meenan, Co-founder and CEO, Analytical Informatics, Inc. (AI) Location: Baltimore, MD Started […]

Comments Off on My Guest Post on BioBuzz: An Interview with Analytical Informatics, Inc. CEO Chris Meenan – Part One Continue Reading →